Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Salonpas pain-relief patch gets TV campaign

Manufacturer Hisamitsu Pharmaceutical has launched a national TV advertising campaign to support its Salonpas Pain Relief patch.

The joint and muscle pain treatment will be promoted on channels including ITV, Channel 4 and Sky 1 throughout February. Hisamitsu would not reveal the spend on the campaign, but said it would focus on the "debilitating pain" caused by strains and sprains, using humanoid statues to illustrate the feeling of sufferers being "trapped inside their bodies".

Photo: Fox Kalomaski Crossing

The Salonpas Pain Relief patch contains methyl salicylate and levomenthol to provide an analgesic and anti-inflammatory effect.

Users can wear the patch "comfortably and discreetly" while carrying out everyday activities, the manufacturer said. A pack of three patches has a recommended retail price of £4.99.

For more information, visit salonpas.co.uk or call Ceuta Healthcare on 0844 243 6661  

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD015973

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel